Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

October 31, 2013

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment

Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks

Trial Locations (7)

613

Chiayi City

807

Kaohsiung City

970

Hualien County

8330

Kaohsiung City

33305

Taoyuan District

Unknown

Taichung

Taipei

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY